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Summary: The submaxillary gland and kidney of diabetic and hypertensive rats were compared for their
content of glandular kallikrein and the activities of tonin and renin. The submaxillary glands and the kidneys
of both diabetic Wistar strain and hypertensive rats contained significantly less glandular kallikrein than
non-diabetic Wistar strain and hypertensive rats (reduction from 40 to 76%). The renin activity of the kidney
showed only a slight change in spite of diabetes, -whereas the activity of the submaxillary gland decreased in
parallel with the reduction of the kallikrein content when diabetes was induced. On the other hand, the tonin
of the submaxillary gland, which has a potent hypertensive activity like renin, was not affected by induction
of diabetes. Höwever, the tonin activity in hypertensive rats was significantly higher (p < 0.001) than that
in the normotensive rats (His-Leu, 168.7 ± 10.1 vs. 131.5 ± 17.3 nmol/min · mg protein).
Drüsen-Kallikrein, Renin und fonin in Geweben diabetischer und hypertensiver Ratten
Zusammenfassung: Die Gl. submaxillaris und die Niere diabetischer und hypertensiver Ratten werden
hinsichtlich ihres Gehalts an Drüsen-Kallikrein sowie ihrer Aktivitäten an Tonin und Renin verglichen. Die
Gl. submaxillaris und die Nieren der diabetischen Wistar-Ratten und der zugleich hypertensiven Ratten
enthielten signifikant weniger Drüsen-Kallikrein als die nicht-diabetischer Wistar-Ratten und hypertensiver
Ratten (Venninderung zwischen 40 und 76%). Die Renin-Aktivität der Nieren zeigte nur geringe Änderungen
durch den Diabetes, während die der GL submaxillaris parallel zur Verminderung des Kallikreingehalts
verlief, wenn Diabetes ausgelöst wurde. Andererseits war Tonin, das Renin-ähnlich wirkt, in der Gl. submaxil-
laris durch den Diabetes nicht beeinflußt, jedoch bei hypertensiven Ratten signifikant höher (p < 0,001) als
bei nonnotensiven Ratten (His-Leu, 168,7 ± 10,1 gegenüber 131,5 ± 17,3 nmol/min · mg Protein).
introduction kidney is known to act on a natural Substrate of
Glandular kallikrein, an enzymeof the serine protein- plasma, angiotensinogen, to release angiotensin I.
äse family, is known to act on a natural Substrate of The latter is converted to angiotensin II, vasopressor
plasma, kininogen, to release a vasodilator peptide, peptide, by angiotensin converting enzyme (2, 3).
kinin (1). On the other band, renin in salivary gland Tonin, another enzyme of the serine protease family,
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is present in salivary gland and has been known not
only to convert angiotensin I to angiotensin II, but
also to generate angiotensin II from a natural sub-
strate of renin, the angiotensinogen (4).
In our previous papers, we have reported that the
kallikrein levels in the submaxillary gland and pan-
creas of diabetic rats were significantly lower than
those of normal rats, and that the submaxillary gland
and pancreatic levels in hypertensive rats tended to
be higher than in normal rats (5). Suzuki et al. have
reported that there are close interactions between the
kallikrein-kinin System and renin-angiotensin System
(6).
The purpose of this present study was to clarify the
relationship between the contents of kallikrein, renin
and tonin in the submaxillary gland and kidney of
diabetic and hypertensive rats.
Materials and Methods
Male Wistar strain rats, spontaneously hypertensive rat strain
and Wistar-kyoto strain (weighing 150—200 g and 7 — 8 weeks
old) were purchased from the Institute for animal experiment,
School of Medicine, Hokkaido University.
Streptozotocin-diabetic rats were induced by a single intrave-
nous injection of streptozotocin (70 mg/kg).
Twenty eight days after injection of streptozotocin, the blood
of treated and control rats were obtained by cardiac puncture
with 1/10 volumes of 38 g/l trisodium citrate, under light
ethylether anaesthesia.
After blood collection, the kidney and the submaxillary gland
were carefully removed from each animal, washed in saline to
remove any traces of blood, and immediately frozen at — 30 °C
to be stored until use.
The levels of blood glucose and systolic pressure of rats were
measured by glucose oxidase method (7) and tail cuff sphyg-
mography.
Protein was determined by the method of Lowry et al. (8),
using bovine serum albumin äs the Standard.
The homogenates of the submaxillary gland and the kidney
were prepared in 10 mmol/1 sodium phosphate buffer (pH 6.0),
containing 100 mmol/1 NaCl (l g of tissue per 9 ml of buffer),
using a Polytron homogenizer. Homogenates were centrifuged
for 20 min at 10000 min-1. The supernatant was used for the
measurement of kallikrein, tonin, and renin.
The contents of glandular kallikrein in the submaxillary gland
and kidney was measured by specific enzyme immunoassay äs
described previously (5).
Renin activity was measured by the rate of generation of angiot-
ensin I in nephrectomized rat plasma (substrate) äs follows:
after incubation with Substrate (25 ) at 37 °C for l h in 100
mmol/1 maleate buffer (pH 6.5) containing 6.0 mmol/1 EDTA
and 2.0 mmol/1 phenylmethanesulphonyl fluoride.
Angiotensin I was determined by the radioimmunoassay
methods of Inagami & Murakami (9), and Haber et al. (10).
Tonin activity was measured in a 3.0 ml incubation mixture
containing 50 mmol/1 boraxphosphate buffer (pH 7.0) äs de-
scribed previously (l 1). EDTA (4.3 mmol/1), phenylmethanesul-
phonyl fluoride (1.43 mmol/1) and dipyridyl (0.141 mmol/1)
were added to the buffer solution to inhibit the angiotensin I-
converting enzyme activity. The reaction was initiated by the
addition of the substrate (angiotensin I, 100 § per tube)
and the reaction mixture was incubated at 37 °C for 30 min.
Reactions were terminated by the addition of 0.4 ml of 2 mol/1
NaOH. To this reaction mixture, ;q-phthalaldehyde reagent
(l g/l methanoi, prepared freshly daüy) (0.1 ml) was added,
then mixed with shaking. Four minutes later at room tempera-
ture, 3.5 mol/1 orthophosphoric acid (0.4 ml) was added to
the mixture. The fluorescence was measured at 440 nm with
excitation at 360 nm. The concentration of His-Leu released
was calculated by a comparison of the fluorescence produced
with Standard Solutions.
Results
Kallikrein content and renin and tonin activities in the
submaxillary gland homogenates of normal, diabetic
and hypertensive rats
As shown in table l, the content of kallikrein in the
submaxillary gland homogenates was 73.5 ± 27.2
and 66.3 + 7.0 \ig/mg protein in normal rats (Wistar
and Wistar-kyoto strains), 17.4 + 9.9 in diabetic
Wistar strain rats, 78.4 ± 8.0 in hypertensive rats,
and 20.4 + 6.4 in diabetic hypertensive rats. On the
other hand, the specific activity of renin in hyperten-
sive rats was 152.7 + 14.55 ng angiotensin I per
h · mg protein, with a significant difference
(p < 0.001) from that in normotensive rats (89.7 ±
13.30). However, the activity was reduced in both
diabetic Wistar strain and hypertensive rats, namely
to 20.9 + 6.58 and 33.0 ± 9.66, respectively. Oü the
other hand, the tonin activity of the submaxillary
gland was not reduced even though diabetes was
induced by streptozotocin injection; the tonin activi-
ties of the diabetic Wistar and hypertensive rats were
86.4 ± 6.82 and 170.2 ± 5.97 nmol His-Leu per
min · mg protein, respectively. In contrast to diabetes,
the control value in the Wistar rats was 98.1 ± 4.21
nmol His-Leu per min · mg protein, and 131.5 *
17.3 in Wistar-kyoto strain rats. The activity of the
hypertensive rats was 168.7 ± 10.10 nmol His-Leu
per min · mg protein, with a significant difference
(p < 0.001) from that in normotensive rats.
Kallikrein content and renin activity in the kidney
homogenates of normal, diabetic and hypertensive rats
The content of kallikrein in the kidney homogenates
was very small in comparison with the submaxillary
gland, äs shown in table 2. As in the submaxillary
gland, the kallikrein content of kidney hoinogenate
decreased in the pathogenesis of experirnental dia-
betes. The values were 8.1 ± 1.09 ng/mg protein in
normal rats (Wiatar), 4.6 ± J:98 in Wistar diabetic
rats, and 3.7 ± 2.26 in diabetic hypertensive rats.
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Tab. 1. Kallikrein content, renin and tonin activities in the submaxillary gland of control, streptozotocin-diabetic, and spon-
taneously hypertensive rats.
Wistar strain
Control (n = 11)
Diabetic (n = 10)
Wistar-kyoto strain
Normotensive (n == 10)
Hypertensive (n = 10)












































* Standard deviation; N. D., not determined.





(angiotensin I, ng/h · mg protein)
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Diabetic (n = 10)
Wistar-kyoto strain
Normotensive (n = 10)
Hypertensive (n = 10)











Standard deviation; N. D., not determined.
However, the kallikrein eontent in hypertensive rats
was 26% lower than that of normotensive rats (5.9
± 1.22vs. 8.0 ± 1.32).
On the other band, the specific activity of renin in
the kidney hpmogenätes showed only slight changes
in hypertension and diabetes. The renin activity of
Wistar rats was 946 ± 139.0 (angiotensin I, ng/h · mg
protein), which was apprpximately the same äs the
value in hypertensive rats (893 + 177.8), although
the activity in Wistar diabetic rats (l 175 ± 149.4) was
significantly higher (p < 0.005) than that of Wistar
control fats.
Discussion
The importance of the renin-angiotensin System in
the aetiology of some forms of hypertension is undis-
puted, and glandular kallikrein has been implicated
in the regulation ofbkxxfflow to the exocrine glands
and kidney, in water and electrolyte balance, and is
also involved in the mediation of insulin action on
blood glucose uptake by the skeletal muscle, and in
the pathogenesis of experimental and human hyper-
tension (12—15). Powers et al. and Celler et al. re-
ported that glandular kallikrein in urine and the
anterior pituitary decreased in hypertensive rats in
comparison with the normal rats (16,17). In contrast,
we have previously reported that the glandular kalli-
krein content of the submaxillary gland tended to be
higher than in normal rats (5), in spite of the fact
that the submaxillary gland is a major source of
glandular kallikrein in rat plasma (18). In order to
clarify the discrepancy, the interrelation of the kalli-
krein-kinin, renin-angiotensin, and tonin-angiotensin
Systems in the submaxillary gland and the kidney
were investigated in normal, hypertensive and dia-
betic rats.
Although the kallikrein of the submaxillary gland in
hypertensive rats was higher than in the normotensive
rats, the kallikrein in diabetic hypertensive rats de-
creased to the same level äs in diabetic Wistar rats.
However, the blood pressure showed only minor
changes in spite of the remarkable reduction of the
submaxillary gland kallikrein. On the other hand, the
tonin activity of the submaxillary gland in hyperten-
sive rats increased 28 — 29% in comparison with nor-
motensive rats. Also, both the high tonin activity and
high blood pressure in hypertensive rats were not
J. Clin. Chem, Clin. Biochem. / Vol. 24,1986 / No. 7
440 Sakamoto et al.: Glandular kallikrein, renin and tonin in rat tissues
changed by the induction of diabetes. Garcia et al.
reported that the tonin concentration of the submax-
illary gland in one-kidney hypertensive rats was sig-
nificantly higher (p < 0.001) than in normotensive
rats (19). From these results it may be suggested that
tonin contributes to the maintainance of high blood
pressure in spontaneously hypertensive rats. Never-
theless, the kallikrein and renin in the kidney cannot
be neglected in the pathogenesis of hypertension,
because the renin activity, which has a close interac-
tion with kallikrein, has been implicated in human
hypertension and in experimental hypertension (6,
20, 21). In the present study, the kallikrein content
in the kidney decreased by 43 — 54% in diabetes and
hypertension in comparison with control and normo-
tensive rats. On the other hand, the renin activity of
the kidney in diabetes and hypertension showed slight
changes in comparison with control rats. Kawashima
et al. reported that a direct role of the renin-angioten-
sin system can be excluded in the maintainance of
hypertension'in spontaneous hypertensive rats (22).
This can be concluded from the fact that no signifi-
cant difference of kidney renin activity was seen be-
tween hypertensive and normotensive rats. Recently,
in contrast to our results, Pratt et al. reported that
diabetic rats were found to have lower plasma renin
activity than non-diabetic controls (23). This discrep-
ancy seems to be due to the more prolonged treatment
with alloxan, namely 7 weeks, in comparison with 4
weeks in our experimerit. In addition, it remains to
be clarified whether the plasma renin activity reflects
the renin activities in the submaxillary gland and
kidney in the diabetic state.
Regarding the relationship between diabetes and
glandular kallikrein, the kallikrein content of the
submaxillary gland and kidney in diabetes decreased
significantly (p < 0.005) in comparison with normo-
tensive and hypertensive rats. A decrease in the pan-
creas in diabetes was reported previously (5). The
reduction of the kallikrein content in the kidney in
diabetic rats is in good agreement with the data of
Mayfield et al. (24). They also reported that the
development of hypertension in streptozotocin-dia-
betic rats follows the decrease in renal kallikrein, and
that the abnormality in kallikrein can be prevented
by insulin treatment. This fact may reflect the fact
that insulin treatment normalizes the levels in renal
kallikrein, probably indicating that insulin is neces-
sary for the activation of the enzyme.
In conclusion, from these results the tonin in the
submaxillary gland and the renal kallikrein may play
a role in the regulation of systemic blood pressure.
However, it still remains to be clarified whether these
enzymes release vasoactive substances in vivo, in hy-
pertension and diabetes.
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